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October 20101122 Abstractsisolated to calf veins, and 9 (20%) were coexistent in calf and proximal veins.
Of the isolated calf DVTs, only two progressed to the popliteal vein or
proximal on follow-up. No examined risk factor predicted DVT. Mechanical
prophylaxis was uniformly used, but chemical prophylaxis varied based on
surgeon preference. DVT developed in 19.3% (28 of 145) of patients
receiving prophylactic medication (unfractionated heparin or low-molecu-
lar-weight heparin) and in 41.4% (12 of 29) receiving no medication (P 
.001).
Conclusions: Despite application of mechanical and chemical DVT
prophylaxis, we found a 23% incidence of DVT in hospitalized, nonambu-
latory, neurosurgical patients. No patients with isolated calf DVT had an
embolic complication, and only 11.7% progressed proximally. Although
chemical prophylaxis reduced DVT risk, no factor was sufficiently predictive
to exclude patients from screening. These data substantiate the importancecells were serum starved for 24 hours to synchronize them to the G0 phase.
HCASMCs were then stimulated into the cell cycle and harvested for totalContinuous Inhibition of Poly-ADP Ribose Polymerase Improves
Functional Recovery and Modulates Skeletal Muscle Regeneration
Following Hind Limb Ischemia and Reperfusion
Mounir J. Haurani, Hassan Albadawi, Rabih Houbballah, Bao-Ngoc
Nguyen, Hyung-Jin Yoo, Glen M. LaMuraglia, Michael T. WatkinsMassa-
chusetts General Hospital, Boston, Mass
Introduction and objectives: Poly (ADP)-ribose polymerase (PARP)
inhibition during the acute phase of limb ischemia/reperfusion injury (IR)
has been shown to be protective; however, elevated levels of PARP activity
persists during the chronic phase of reperfusion. The primary goal of these
experiments was to determine whether ongoing post hoc PARP inhibition
potentiated muscle regeneration and functional recovery after IR.
Methods: C57BL6/J mice were subjected to 1.5 hours of unilateral
hind limb ischemia, followed by 2 weeks of reperfusion. During ischemia,of VDUS screening and support revising our protocol to evaluate femoral
and popliteal veins only.
mice were treated with a PARP inhibitor PJ34 (PJ, n 12) by implantation
of a continuous slow-release pellet (10 mg/kg/d for 14 days), or placebo
Table. Outcomes of PARP inhibition
Variable PJ34 Control P
Ambulation score (1  normal, 4  dragging) 1.7 2.8 .001
Peak force muscle contracture, grams 68.1 62.1 .03
PAR expression
Densitometry value 14,288  1276 26,839  5830 .022
Percent immature fibers 8.32  4.70 77.5  8.2 .001
ATP
Tissue level, nmol/mg 5.93  0.27 3.73  0.50 .001
Myogenin
Densitometry value 45,285  6,340 83,531  22,507 .051
Perfusion ratio (injured/noninjured limb) 0.959  0.048 0.921  0.062 .636pellet (control, n  12). Hind limb function was analyzed with ambula-
tion scoring scale and muscle contractility using direct muscle stimula-
tion. Muscle regeneration and PARP activity were assessed by immuno-
blotting for myogenin, a transcription factor associated with myofibers
differentiation, and poly ADP-ribose (PAR). ATP levels were measured
with chemiluminescence. Immature muscle fibers were counted micro-
scopically. Hind limb perfusion ratios were measured by laser-Doppler
imaging.
Results: Inhibition of PARP was confirmed by decreased PAR expres-
sion in PJ mice (see Table). Ambulation scores and muscle contractility were
improved in PJ mice. This improved functional status correlated with a
higher number of mature muscle fibers and preservation of ATP. Myogenin
expression was decreased in PJ mice, but was not significant. These changes
were not due to differences in perfusion based on laser-Doppler imaging
ratios.
Conclusions: Continuous PARP inhibition significantly improves
hind limb function after IR. This improved function is associated with
increased numbers of mature fibers and improved levels of high-energy
phosphate in the muscle. PJ34 may prove to be a pharmacologic treat-
ment useful in ameliorating the effects of reperfusion injury after isch-
emia insult.
A Possible Role for MAP Kinases and MARCKS Interaction in the
Development of Intimal Hyperplasia and Graft Failure
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Introduction and objectives: The myristoylated alanine-rich C-kinase
substrate (MARCKS), a major protein kinase C substrate, is upregulated in
intimal hyperplasia (IH), yet its signaling pathway remains undetermined.
Through inhibition of vascular smooth muscle cell (VSMC) migration and
proliferation, p27kip1, a cyclin-dependent kinase inhibitor, regulates IH. We
have previously demonstrated MARCKS siRNA-mediated knockdown de-
creases VSMC migration and proliferation and increases p27kip1 expression.
The MAP kinases SAP/JNK, p38, and ERK1/2 are important regulators of
the cell cycle and interact with p27kip1. The goal of the present study was to
monitor the protein expression of p38, ERK1/2, and SAP-JNK in the
setting of MARCKS knockdown.
Methods: Human coronary artery smooth muscle cells (HCASMC)
were transfected with 50 nm control, or MARCKS siRNA, or vehicle. Theprotein extraction along different points of the cell cycle (0 and 30 minutes,
18 and 24 hours). Western blot analysis was performed to monitor the
protein expression of MARCKS, p27kip1, p38, ERK1/2, and SAP/JNK.
Results: All of the following results are presented as percent change in
protein expression in MARCKS siRNA-treated HCASMCs compared with
control siRNA-treated HCASMCs. MARCKS siRNA treatment resulted in
(1) 40% to 75% decrease in MARCKS expression at all different time points,
(2) a 30% increase in p27kip1 at all different time points, (3) no change in p38
expression at 0 and 30 minutes and a 25% increase at later time points, (4) no
change in SAP-JNK expression at 0 and 30 minutes and a 30% to 78%
increase at later time points, (5) no change in ERK1/2 expression at all
different time points.
Conclusions: The results of this study shed light on a possible IH
signaling pathway mediated by MARCKS through p27kip1, p38, and SAP-
JNK MAP kinase regulation.
A Novel In Vitro Flow Model That Recapitulates Alterations of Vessel
Identity During Vein Graft Adaptation In Vivo
Lynn Model, Akihito Muto, Clay Quint, Yuka Kondo, Amanda Feigel,
Kenneth Ziegler, Sammy Egbalieh, Laura Niklason, Alan DardikYale Uni-
versity, New Haven, Conn
Introduction and objectives: Conventional in vitro flow models of
vein graft adaptation have not previously characterized the vessels according
to their markers of specificity. In particular, it is not known whether in vitro
models of vein graft adaptation mimic physiologically reduced expression of
the venous determinant ephrin-B4 or whether they stimulate expression of
the arterial determinant ephrin-B2.
Methods: Saphenous vein remnants were taken from the operating
room and immediately placed in a flow circuit. Medium was circulated at 20
dyne/cm2 for 24 hours, and then specimens were analyzed with H&E, von
Giessen, and TUNEL staining. Protein was analyzed using Western blot-
ting, and was RNA analyzed using qPCR.
Results: After 24 hours of arterial flow in vitro, saphenous veins were
viable, with no detectable induction of either activated caspase-3 or PARP
cleavage (n  6); TUNEL staining showed no increase over baseline.
Endothelial cells were identified on the luminal surface, and PECAM was
present both initially and after 24 hours of flow. Ephrin-B4 expression was
diminished (n  6, P  .04), and there was no induction of ephrin-B2
expression (n 6, P .001). Expression of osteopontin (n 7, P .001),
a marker of vein graft adaptation, was increased.
Conclusions: This novel in vitro flow model preserves human saphe-
nous vein viability for at least 24 hours, including vessel endothelium. When
exposed to the bioreactor environment, markers of venous and arterial
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reported in human vein graft adaptation and animal models. These bioreac-
tors adequately mimic the human arterial environment and enable testing of
potential therapeutic agents directed against neointimal hyperplasia.
CTGF is a Marker of Promigratory Subpopulation of Human Vascular
Smooth Muscle Cells: Target for Treatment of Intimal Hyperplasia
Robert Wagner1, Amber Liu2, Richard Powell1, Eva M. Rzucidlo1
1Dartmouth-Hitchcock Medical Center, Lebanon, NH; 2Dartmouth Med-
ical School, Hanover, NH
Introduction and objectives: Understanding the processes that con-
trol vascular smooth muscle cell (VSMC) phenotypic modulation and
determining which subpopulation of VSMCs migrate is critical for the
design of treatment of intimal hyperplasia. Connective tissue growth factor
(CTGF) has recently been reported to be upregulated in a variety of fibrotic
disorders. We hypothesize that CTGF is a marker of a dedifferentiated
VSMCs and therefore a target for treatment of intimal hyperplasia.
Methods: Western blot analysis was used to determine protein expres-
sion. Bowden chambers were used for VSMC migration. Magnetic beads
were labeled with CTGF antibody according to the manufacture’s protocol.
Porcine carotid arteries were microdissected into inner layer (intima/media)
and outer layer (media/adventitia). VSMCs were transfected with myr-
AKT1 using the nucleofection technique. Pig iliac arteries were injured and
organ-cultured for 7 days.
Results: Intimal hyperplastic VSMCs had higher baseline CTGF ex-
pression than normal VSMCs. VSMCs in the inner intimal/medial layer had
increased differentiation markers. Outer medial/adventitial layer VSMCs
had decreased contractile protein expression and increased CTGF expres-
sion. Balloon injury led to increased expression of CTGF in a subpopulation
of VSMC as well as CTGF expression in cells within the intimal hyperplastic
lesion. Intimal hyperplasia was recapitulated by addition of exogenous
CTGF. High-expressing CTGF VSMCs (magnetic bead isolated) had de-
creased contractile protein expression and increased extracellular matrix
expression. CTGF-positive VSMCs had 60% increased migration. Exoge-
nous CTGF increased VSMC migration in a dose-dependent manner.
Overexpression of myr-AKT1 increased CTGF and collagen IV expression
in VSMCs.
Conclusions:CTGF is an important regulator of VSMC migration and
vascular remodeling through AKT1. CTGF is overexpressed in a subpopu-
lation of VSMCs, which may be the promigratory cells that populate intimal
hyperplasia lesions. These data will allow for more targeted therapies for
intimal hyperplasia.
A Prospective Evaluation of the Impact of Balloon-Expandable Palmaz
Stent Placement in Aortic Neck During EVAR
Ivan Dominguez, Manish Mehta, Sean P. Roddy, R. Clement Darling,
Yaron Sternbach, John B. Taggert, Philip S.K. Paty, W. John Byrne, Paul B.
Kreienberg, Kathleen J. Ozsvath, Benjamin B. Chang, Dhiraj M. Shah,
Albany Medical College, Albany, NY
Introduction and objectives: This study evaluated the impact of
balloon-expandable Palmaz stents for treatment of type I endoleaks during
EVAR.
Methods: During an 8-year period, 1378 patients underwent EVAR
using commercially available stent grafts. Patients were categorized into two
groups: (1) adjunctive use of the Palmaz stent for treatment of type I
endoleak during EVAR (EVAR  Palmaz stent: n  146, 11%) and (2)
EVAR without Palmaz stent (EVAR only: n  1232, 89%). Patient fol-
low-up included CTA and duplex ultrasound imaging at 1 and 6 months,
and every 12 months thereafter. Data were prospectively collected in a
vascular registry, and all variables were analyzed.
Results: Of the 1378 patients, the EVAR  Palmaz stent group (n 
146, 11%) had a significantly higher incidence of ischemic colitis (6.9% vs
0.7%, P .05), persistent or new type I endoleaks (13% vs 7%, P .05), type
II endoleaks (32% vs 23%, P  .05), and secondary interventions (31% vs.
19%, P .05). A significantly higher percentage of women required Palmaz
stents during EVAR (17% vs 8%, P .05). The EVAR Palmaz stent group
also had a higher 30-day mortality (3.4% vs 1.4%) and a higher incidence ofstent graft explant (2.7% vs 0.97%), although this difference did not reach
statistical significance (Table).
Conclusions: The adjunctive use of balloon-expandable Palmaz stents
during EVAR is not a benign procedure and increases the risks for develop-
ing ischemic colitis, recurrent type I and type II endoleaks, and requiring
secondary interventions. Furthermore, women have nearly a twofold in-
creased risk or requiring a Palmaz stent during EVAR.
Table. Outcomes of EVAR with and without Palmaz
stent
Variable
EVAR  Palmaz
stent EVAR only P
No. (%) No. (%)
Number 146 (11) 1232 (89)
Female 56 (38) 263 (21) .05
Ischemic colitis 10 (6.9) 19(0.7) .05
Type I endoleak 19 (13) 87(7) .05
Type II endoleak 46 (32) 283(23) .05
Secondary interventions 45 (31) 228(19) .05
Stent graft explant 4 (2.7) 12 (0.97) .12
30-day mortality 5 (3.4) 17(1.4) .17
Bone Marrow Aspirate Concentrate in Critical Limb Ischemia: Results
of a Multicenter Randomized Double-Blind Trial
Mark D. Iafrati1, Dennis Bandyk2, Eric Benoit3, George Geils4, John (Jeb)
Hallett4, Anil Hingorani5, Alan Lumsden6, Gregory Pearl7, Eric Peden6,
Sean Roddy8 1Tufts Medical Center, Boston, Mass; 2University of South
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Corp., Plymouth, Mass; 4Roper St. Francis Hospital, Charleston, SC; 5Mai-
monides Medical Center, Brookyn, NY; 6The Methodist Hospital, Hous-
ton, Tex; 7Baylor Medical Center, Dallas, Tex; 8The Vascular Group,
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Introduction:Bone marrow is rich in progenitor and other supporting
cells. We conducted a pilot study using bone marrow aspirate concentrate
(BMAC) to treat critical limb ischemia (CLI).
Methods: A prospective, randomized, double-blinded, placebo-con-
trolled pilot study was conducted at eight centers. Patients with critical climb
ischemia (ABI0.4, TBI0.4, or TcPO220), Rutherford clinical class 4
or 5, who were poor candidates for conventional revascularization were
enrolled with 2 (BMAC):1 (control) randomization. BMAC patients under-
went a 240-mL aspiration. The control group underwent a bilateral 1-mL
aspiration. Bone marrow was concentrated in the operating room using an
automated, decanting centrifuge. The placebo injectate was created from
peripheral blood. The blinded treatment team injected the material into the
extremity in a series of 40 1-mL injections.
Results: A total of 48 patients were treated using conscious sedation
between November 2007 and October 2009, comprising 32 men (67%);
mean age, 69 (range, 42-93). At the 12-week follow-up, there were no
deaths and nine major limb amputations: four (28.6%) in controls and five
(14.7%) in BMAC. Adverse events were reported in 74% of BMAC and 64%
of controls, none related to the study treatment. ABIs were unchanged in
controls but increased by 0.1 in BMAC patients (P .01). Pain assessed on
a 100-mm scale improved (decreased 30 mm) in 11 of 25 BMAC (44%)
and in 2 of 8 controls (25%). We developed a composite index: patients were
“improved” if they survived without a major amputation and their Ruther-
ford clinical class and/or pain decreased. Composite improvement was
noted in 16 of 31 BMAC (52%) vs 3 of 13 controls (23%; P  .1).
Conclusions: BMAC holds great promise for the treatment of CLI.
Our composite index incorporates the major relevant determinants of suc-
cess in advanced CLI, with BMAC patients achieving twice the success of
controls. A robust pivotal trial is needed to verify and expand on these
preliminary results.
